Literature DB >> 12655082

Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells.

Dongsheng Li1,2, Seyed Taghi Takyar1,2, William B Lott1,2, Eric J Gowans1,2.   

Abstract

A self-modulating mechanism by the hepatitis C virus (HCV) core protein has been suggested to influence the level of HCV replication, but current data on this subject are contradictory. We examined the effect of wild-type and mutated core protein on HCV IRES- and cap-dependent translation. The wild-type core protein was shown to inhibit both IRES- and cap-dependent translation in an in vitro system. This effect was duplicated in a dose-dependent manner with a synthetic peptide representing amino acids 1-20 of the HCV core protein. This peptide was able to bind to the HCV IRES as shown by a mobility shift assay. In contrast, a peptide derived from the hepatitis B virus (HBV) core protein that contained a similar proportion of basic residues was unable to inhibit translation or bind the HCV IRES. A recombinant vaccinia-HCV core virus was used to examine the effect of the HCV core protein on HCV IRES-dependent translation in cells and this was compared with the effects of an HBV core-recombinant vaccinia virus. In CV-1 and HuH7 cells, the HCV core protein inhibited translation directed by the IRES elements of HCV, encephalomyocarditis virus and classical swine fever virus as well as cap-dependent translation, whereas in HepG2 cells, only HCV IRES-dependent translation was affected. Thus, the ability of the HCV core protein to selectively inhibit HCV IRES-dependent translation is cell-specific. N-terminal truncated (aa 1-20) HCV core protein that was expressed from a novel recombinant vaccinia virus in cells abrogated the inhibitory phenotype of the core protein in vivo, consistent with the above in vitro data.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655082     DOI: 10.1099/vir.0.18697-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Wei Zhou; Li-Yun Zou
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Molecular biology of hepatitis C virus.

Authors:  Tetsuro Suzuki; Hideki Aizaki; Kyoko Murakami; Ikuo Shoji; Takaji Wakita
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

4.  Lethiferous effects of a recombinant vector carrying thymidine kinase suicide gene on 2.2.15 cells via a self-modulating mechanism.

Authors:  Quan-Cheng Kan; Zu-Jiang Yu; Yan-Chang Lei; Lian-Jie Hao; Dong-Liang Yang
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

5.  Differential effects on the hepatitis C virus (HCV) internal ribosome entry site by vitamin B12 and the HCV core protein.

Authors:  Dongsheng Li; William B Lott; John Martyn; Gholamreza Haqshenas; Eric J Gowans
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Li-Yun Zou; Wei Zhou
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

7.  Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly.

Authors:  Peter Friebe; Ralf Bartenschlager
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

8.  The evaluation of hepatitis C virus core antigen in immunized BALB/c mice.

Authors:  Elham Torbati; Mojgan Bandehpour; Parviz Pakzad; Nariman Mosaffa; Ameneh Koochaki; Bahram Kazemi
Journal:  Hepat Mon       Date:  2012-06-30       Impact factor: 0.660

9.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08

10.  The hepatitis C virus core protein can modulate RNA-dependent RNA synthesis by the 2a polymerase.

Authors:  Y Wen; C Cheng Kao
Journal:  Virus Res       Date:  2014-05-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.